Psoriasis and Psoriatic Arthritis: A Strategic Analysis of the Market in the United States
This report focuses on the applications of current and advanced therapeutics to the treatment of psoriasis and psoriatic arthritis, the options they present, and the progress that is being made in these fields. The major market effects of new therapeutics, with the potential of a breakthrough drug always a possibility, are expected to be seen over the next ten years. The technology trends selected in conjunction with the growing interest in psoriasis and its treatment present the most informative picture of advances in psoriasis and psoriatic arthritis therapeutics and the markets that result.
The report’s market analysis includes:
- extensive discussion of the pathology of the multiple forms of the disease
- thorough examination of the epidemiology in the United States segmented by severity and projected to 2016
- comprehensive analysis of the total available market and serviceable available market for psoriasis (by severity) and psoriatic arthritis through 2016
- monthly cost per patient forecasts for psoriasis (by severity) and psoriatic arthritis through 2016
In depth company profiles of major competitors and a meticulous review of the expert conclusions and strategic implications for competitors serious about winning in the psoriasis therapeutics field round out this systematic analysis.
The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including immunologists, dermatologists, rheumatologists, pathologists, research scientists, business development managers and marketing managers.
Table of Contents
Chapter One: Executive Summary
- Overview
- Types
- Scope and Methodology
- Market Analysis
- Trends and Considerations
CHAPTER Two: Pathology and Epidemiology
- Overview
- Tumor Necrosis Factor á
- Contributing Factors
- National Psoriasis Foundation Survey
- Daily Life Impacts
- Problems Receiving Services Due to Perception of Their Disease
- Quality of Life
- Pathology of Psoriasis
- Types
- Plaque Psoriasis
- Guttate Psoriasis
- Inverse Psoriasis
- Pustular Psoriasis
- Erythrodermic Psoriasis
- Types by Location
- Scalp Psoriasis
- Types by Severity
- Pathology of Psoriatic Arthritis
- The Genetics of Psoriasis and Psoriatic Arthritis
- Psoriasis and Psoriatic Arthritis Epidemiology
CHAPTER Three: Current Therapies
- Topical Therapy
- Anthralin
- Calcipotriene
- Coal Tar
- Salicylic Acid
- Corticosteroids (Steroids)
- Vitamin A
- Sunlight and Water (Climatotherapy)
- Phototherapy
- UV-B Therapy
- PUVA
- Systemic Treatments
- Corticosteroids
- Cyclosporine
- Methotrexate
- Retinoids
- Aspirin and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Biological DMARDS
- T-Cell Agents
- Monoclonal TNF Antibodies
- Soluble TNF Receptor Inhibitors
- New Developments
- Alternative Therapies
- Acupuncture
- Ayurvedic Medicine
- Chinese Medicine
- Chiropractic
- Homeopathic Medicine
- Naturopathic Medicine
- Glucosamine and Chondroitin
- Methylsulfonylmethane (MSM)
- S-adenosylmethionine (SAM-e)
- Magnetic Therapy
CHAPTER Four: Market Analysis
- Forecasting Challenges
- Market Size and Cost of Treatment
- Total Available Market vs Serviceable Available Market
- Competition
CHAPTER Five: Company Profiles
- Amgen
- Angiotech Pharmaceuticals
- Biogen IDEC
- Centocor, Inc.
- Galderma Laboratories
- Isis Pharmaceuticals, Inc.
- Isotechnika, Inc.
- Ligand Pharmaceuticals
- Vertex Pharmaceuticals
CHAPTER Six: Conclusions and Strategic Implications
- First Conclusion
- Implications:
- Second Conclusion
- Implications:
- Third Conclusion
- Implications:
- Fourth Conclusion
- Implications:
- Fifth Conclusion
- Implications:
- Sixth Conclusion
- Implications:
- Seventh Conclusion
- Implications:
- Eighth Conclusion
- Implications:
- Appendix: Company Directory
List of Exhibits
Chapter One: Executive Summary
- Table 1-1: Prevalence of Psoriasis and Psoriatic Arthritis in the United
- States 2006-2016
- Figure 1-1: Distribution of Psoriasis Cases in the United States by Severity: 2006
- Table 1-2: Common Psoriasis Treatments
- Table 1-3: The Total Available Market for Psoriasis and Psoriatic Arthritis Therapeutics in the United States by Severity 2006-2016
- Figure 1-2: Trending in the Total Available Market (TAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States: 2006-2016
- Table 1-4: Serviceable Available Market (SAM) for Psoriasis and Psoriatic
- Arthritis Therapeutics in the United States by Severity 2006-2016
- Figure 4-3: Trending in the Serviceable Available Market (SAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States: 2006-2016
CHAPTER Two: Pathology and Epidemiology
- Table 2-1: Types of Psoriasis and Their Characteristics
- Table 2-2: Psoriasis Assessment Methods
- Table 2-3: Type of Psoriatic Arthritis (PsA) and Their Characteristics
- Table 2-4: Prevalence of Psoriasis and Psoriatic Arthritis in the United States by Type 2006-2016
- Figure 2-1: Prevalence of Psoriasis, by Severity, in the United States 2006-2016
- Figure 2-2: Prevalence of Psoriasis and Psoriatic Arthritis in the United
- States 2006-2016
CHAPTER Three: Current Therapies
- Table 3-1: Psoriasis and Psoriatic Arthritis Therapeutics and Treatment
- Products
- Table 3-2: The Psoriasis Treatment Ladder
- Table 3-3: Steroid Potency Classes and Products
- Table 3-4: Phototherapy Skin Types
- Table 3-5: Phototherapy Equipment Manufacturers
- Table 3-6: Comparison of Biological Therapeutics for Psoriasis and Psoriatic Arthritis
- Table 3-7: Treatments in Development for Psoriasis and Psoriatic Arthritis
CHAPTER Four: Market Analysis
- Table 4-1: Total Available Market (TAM) for Psoriasis (by Severity) and
- Psoriatic Arthritis Therapeutics in the United States 2006-2016
- Figure 4-1: Trending in the Total Available Market (TAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States: 2006-2016
- Figure 4-2: Composition of the Total Available Market (TAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States: 2006-2016
- Table 4-2: Estimated Monthly Cost per Patient for the Medicinal Treatment of Psoriasis (by Severity) and Psoriatic Arthritis in the United States2006-2016
- Table 4-3: Serviceable Available Market (SAM) for Psoriasis (by Severity) and Psoriatic Arthritis Therapeutics in the United States: 2006-2016
- Figure 4-3: Trending in the Serviceable Available Market (SAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States 2006-2016
- Figure 4-4: Composition of the Serviceable Available Market (SAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States 2006-2016
- Table 4-4: Active Competitors in Ethical Pharmaceuticals for Psoriasis andPsoriatic Arthritis in the United States
- Figure 4-3: Trending in Average Monthly Medicinal Treatment Costs for Psoriasis (by Severity) and Psoriatic Arthritis: 2006-2016
Other users found this report page using the following search terms: psoriasis psoriatic arthritis rheumatoid arthritis autoimmune pathology arthritis psoriatic psoriasis market total acupuncture treatment prevalence 2006
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.